|

Peluntamig (PT217) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1/2: 1

Top Sponsors

  • Phanes Therapeutics1

Indications

  • Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)1
  • Neuroendocrine Prostate Cancer (NEPC)1
  • Large Cell Neuroendocrine Cancer (LCNEC)1
  • Neuroendocrine Carcinomas (NEC)1
  • Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)1

Duarte, California1 trial

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.